Cargando…
Decentralised clinical trials in multiple sclerosis research
Randomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been evolving to improve the robustness of their designs and the efficiency of their...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972228/ https://www.ncbi.nlm.nih.gov/pubmed/35735014 http://dx.doi.org/10.1177/13524585221100401 |
_version_ | 1784898278113935360 |
---|---|
author | Garjani, Afagh Liu, Brandon Jun-Yu Allen, Christopher Martin Gunzler, Douglas David Gerry, Stephen William Planchon, Sarah Marie das Nair, Roshan Chataway, Jeremy Tallantyre, Emma C Ontaneda, Daniel Evangelou, Nikos |
author_facet | Garjani, Afagh Liu, Brandon Jun-Yu Allen, Christopher Martin Gunzler, Douglas David Gerry, Stephen William Planchon, Sarah Marie das Nair, Roshan Chataway, Jeremy Tallantyre, Emma C Ontaneda, Daniel Evangelou, Nikos |
author_sort | Garjani, Afagh |
collection | PubMed |
description | Randomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been evolving to improve the robustness of their designs and the efficiency of their conduct. Advances in digital and mobile technologies in recent years have facilitated this process and the first RCTs with decentralised elements became possible. Decentralised clinical trials (DCTs) are conducted remotely, enabling participation of a more heterogeneous population who can participate in research activities from different locations and at their convenience. DCTs also rely on digital and mobile technologies which allows for more flexible and frequent assessments. While hospitals quickly adapted to e-health and telehealth assessments during the COVID-19 pandemic, the conduct of conventional RCTs was profoundly disrupted. In this paper, we review the existing evidence and gaps in knowledge in the design and conduct of DCTs in MS. |
format | Online Article Text |
id | pubmed-9972228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-99722282023-03-01 Decentralised clinical trials in multiple sclerosis research Garjani, Afagh Liu, Brandon Jun-Yu Allen, Christopher Martin Gunzler, Douglas David Gerry, Stephen William Planchon, Sarah Marie das Nair, Roshan Chataway, Jeremy Tallantyre, Emma C Ontaneda, Daniel Evangelou, Nikos Mult Scler Topical Review Randomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been evolving to improve the robustness of their designs and the efficiency of their conduct. Advances in digital and mobile technologies in recent years have facilitated this process and the first RCTs with decentralised elements became possible. Decentralised clinical trials (DCTs) are conducted remotely, enabling participation of a more heterogeneous population who can participate in research activities from different locations and at their convenience. DCTs also rely on digital and mobile technologies which allows for more flexible and frequent assessments. While hospitals quickly adapted to e-health and telehealth assessments during the COVID-19 pandemic, the conduct of conventional RCTs was profoundly disrupted. In this paper, we review the existing evidence and gaps in knowledge in the design and conduct of DCTs in MS. SAGE Publications 2022-06-23 2023-03 /pmc/articles/PMC9972228/ /pubmed/35735014 http://dx.doi.org/10.1177/13524585221100401 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Topical Review Garjani, Afagh Liu, Brandon Jun-Yu Allen, Christopher Martin Gunzler, Douglas David Gerry, Stephen William Planchon, Sarah Marie das Nair, Roshan Chataway, Jeremy Tallantyre, Emma C Ontaneda, Daniel Evangelou, Nikos Decentralised clinical trials in multiple sclerosis research |
title | Decentralised clinical trials in multiple sclerosis
research |
title_full | Decentralised clinical trials in multiple sclerosis
research |
title_fullStr | Decentralised clinical trials in multiple sclerosis
research |
title_full_unstemmed | Decentralised clinical trials in multiple sclerosis
research |
title_short | Decentralised clinical trials in multiple sclerosis
research |
title_sort | decentralised clinical trials in multiple sclerosis
research |
topic | Topical Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972228/ https://www.ncbi.nlm.nih.gov/pubmed/35735014 http://dx.doi.org/10.1177/13524585221100401 |
work_keys_str_mv | AT garjaniafagh decentralisedclinicaltrialsinmultiplesclerosisresearch AT liubrandonjunyu decentralisedclinicaltrialsinmultiplesclerosisresearch AT allenchristophermartin decentralisedclinicaltrialsinmultiplesclerosisresearch AT gunzlerdouglasdavid decentralisedclinicaltrialsinmultiplesclerosisresearch AT gerrystephenwilliam decentralisedclinicaltrialsinmultiplesclerosisresearch AT planchonsarahmarie decentralisedclinicaltrialsinmultiplesclerosisresearch AT dasnairroshan decentralisedclinicaltrialsinmultiplesclerosisresearch AT chatawayjeremy decentralisedclinicaltrialsinmultiplesclerosisresearch AT tallantyreemmac decentralisedclinicaltrialsinmultiplesclerosisresearch AT ontanedadaniel decentralisedclinicaltrialsinmultiplesclerosisresearch AT evangelounikos decentralisedclinicaltrialsinmultiplesclerosisresearch |